Trials / Completed
CompletedNCT00373646
Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients
Phase II Trial of Thalidomide (Thalidomide Pharmion) in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Medical University of Vienna · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate Thalidomide for treatment of disseminated MALT Lymphoma or at relapse following helicobacter pylori (HP) - eradication or chemotherapy or radiation.
Detailed description
The objectives of this study are to evaluate the effectivity and the safety of thalidomide in patients with disseminated MALT lymphoma or at relapse following HP-eradication, or chemotherapy or radiation. It is a phase II prospective single arm study with a target sample size of 16 patients. Thalidomide is given orally at an initial dose of 100 mg for a maximum duration of 6 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Thalidomide, Pharmion | 200 mg p.o. daily |
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2006-09-08
- Last updated
- 2009-06-18
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT00373646. Inclusion in this directory is not an endorsement.